SG11202001401TA - Separation of triple-light chain antibodies using cation exchange chromatography - Google Patents

Separation of triple-light chain antibodies using cation exchange chromatography

Info

Publication number
SG11202001401TA
SG11202001401TA SG11202001401TA SG11202001401TA SG11202001401TA SG 11202001401T A SG11202001401T A SG 11202001401TA SG 11202001401T A SG11202001401T A SG 11202001401TA SG 11202001401T A SG11202001401T A SG 11202001401TA SG 11202001401T A SG11202001401T A SG 11202001401TA
Authority
SG
Singapore
Prior art keywords
triple
separation
light chain
cation exchange
exchange chromatography
Prior art date
Application number
SG11202001401TA
Inventor
Fang Liu
Xinfang Li
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11202001401TA publication Critical patent/SG11202001401TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202001401TA 2017-09-22 2018-09-21 Separation of triple-light chain antibodies using cation exchange chromatography SG11202001401TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562188P 2017-09-22 2017-09-22
PCT/US2018/052212 WO2019060718A1 (en) 2017-09-22 2018-09-21 Separation of triple-light chain antibodies using cation exchange chromatography

Publications (1)

Publication Number Publication Date
SG11202001401TA true SG11202001401TA (en) 2020-04-29

Family

ID=65810610

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001401TA SG11202001401TA (en) 2017-09-22 2018-09-21 Separation of triple-light chain antibodies using cation exchange chromatography

Country Status (12)

Country Link
US (1) US20190112359A1 (en)
EP (1) EP3684409A4 (en)
JP (2) JP2020534332A (en)
KR (1) KR20200056396A (en)
CN (1) CN111163804A (en)
AU (1) AU2018338205A1 (en)
CA (1) CA3073414A1 (en)
IL (1) IL272849A (en)
MA (1) MA50195A (en)
SG (1) SG11202001401TA (en)
TW (1) TWI826393B (en)
WO (1) WO2019060718A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
JP7203497B2 (en) 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド Anti-CD123 Antibodies, and Conjugates and Derivatives Thereof
TW202100557A (en) 2019-04-29 2021-01-01 美商免疫遺傳股份有限公司 Biparatopic fr-alpha antibodies and immunoconjugates
KR20220004669A (en) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 Therapeutic Combinations Comprising Anti-CD123 Immunoconjugates
EP4028420A1 (en) 2019-09-13 2022-07-20 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
RU2498991C2 (en) * 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
JP2011509675A (en) 2008-01-18 2011-03-31 メディミューン,エルエルシー Cysteine engineered antibodies for site-specific conjugation
JP5918129B2 (en) 2009-06-22 2016-05-18 メディミューン,エルエルシー Engineered Fc region for site-specific conjugation
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
ES2843546T3 (en) * 2014-04-18 2021-07-19 The Research Foundation Of The State Univ Of New York Humanized anti-TF-antigen antibodies
JP7203497B2 (en) * 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド Anti-CD123 Antibodies, and Conjugates and Derivatives Thereof
SI3313845T1 (en) 2015-06-29 2021-01-29 Immunogen, Inc. Conjugates of cysteine engineered antibodies

Also Published As

Publication number Publication date
TWI826393B (en) 2023-12-21
MA50195A (en) 2020-07-29
AU2018338205A1 (en) 2020-05-07
JP2020534332A (en) 2020-11-26
US20190112359A1 (en) 2019-04-18
KR20200056396A (en) 2020-05-22
IL272849A (en) 2020-04-30
JP2023112042A (en) 2023-08-10
RU2020107752A (en) 2021-10-22
CN111163804A (en) 2020-05-15
EP3684409A4 (en) 2021-06-23
WO2019060718A1 (en) 2019-03-28
RU2020107752A3 (en) 2022-04-27
CA3073414A1 (en) 2019-03-28
EP3684409A1 (en) 2020-07-29
TW201915011A (en) 2019-04-16

Similar Documents

Publication Publication Date Title
HK1257164A1 (en) Novel anti-pd-l1 antibodies
IL255727A (en) Novel anti-pd-l1 antibodies
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295B1 (en) Anti-pd-l1 antibodies
HK1246324A1 (en) Anti-pd-l1 antibodies
IL261188A (en) Antibodies to tigit
IL257062A (en) Novel anti-pd-1 antibodies
ZA201803874B (en) Humanized anti-cd73 antibodies
HK1249114A1 (en) Monoclonal antibodies against bcma
RS61204B1 (en) Anti-pd-1 antibodies
EP3433277A4 (en) Novel anti-pd-l1 antibodies
IL272849A (en) Separation of triple-light chain antibodies using cation exchange chromatography
HK1258375A1 (en) Humanized anti-cll-1 antibodies
IL273393A (en) Novel anti-cd3epsilon antibodies
IL256579A (en) Humanized antibodies
ZA201901865B (en) Anti-pd-1 antibodies
IL262776A (en) Humanized anti-il-1r3 antibodies
HK1250046A1 (en) Anti-dkk-1-anti-rankl bispecific antibody compounds
PL3371216T3 (en) Humanized anti-bag3 antibodies
GB201609742D0 (en) Improvements relating to antibodies
IL253518A0 (en) Assays for highlypositively charged protein
GB201511196D0 (en) Monoclonal antibodies
IL272015A (en) Antibodies to MADCAM